G2Gbio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
G2Gbio is a South Korean biotech company listed on KOSDAQ, Korea's tech-focused small-cap exchange, that works in the development of pharmaceutical and biological products.
Its products are aimed at medical and health-care end users. The filing's business description section contains only a table-of-contents entry and does not disclose specific products, services, or structural details, so no further factual characterisation can be confirmed from the available text.
Summary is AI-generated and may contain errors · figures from DART filings
G2Gbio in five facts
What does G2Gbio do?
G2Gbio is a South Korean biotech company listed on KOSDAQ, Korea's tech-focused small-cap exchange, that works in the development of pharmaceutical and biological products.
Where is G2Gbio listed and in which sector?
G2Gbio (Korean name: 지투지바이오) trades under KRX code 456160 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is G2Gbio?
Its market capitalisation was US$528.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were G2Gbio's latest annual revenue and operating profit?
For fiscal year 2025, G2Gbio reported revenue of US$319.3K, an operating loss of US$9.2M and a net loss of US$9.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 45.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material management matter relevant to investment decisionsOct 19
- Conversion price adjustmentSep 23
- DisclosureSep 14
- Conversion price adjustmentSep 14
- Material event report (convertible bonds)
G2Gbio disclosed convertible bonds to raise US$13.3M, about 2.8% of its market value.
Capital raise · Mar 16 - [Amended] Material event report (rights offering)
G2Gbio updated the terms of convertible bonds to raise US$51.3M, about 10.5% of its market value.
Capital raise · Mar 5 · 2 versions - [Amended] Material event report (convertible bonds)
G2Gbio updated the terms of convertible bonds to raise US$51.3M, about 10.5% of its market value.
Capital raise · Mar 5 · 2 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
G2Gbio reported separate results for FY2025: revenue of US$292K (−45% year on year), an operating loss of US$8.42M and a net loss of US$8.34M.
Earnings · Feb 2